Company Profiles

driven by the PitchBook Platform

MerLion Pharmaceuticals

Description

Developer of anti-bacterial drugs for the treatment of urinary tract infections. The company engages in research and development of anti-bacterial drugs for the treatment of urinary tract infections and the eradication of helicobacter pylori.

2002

Founded

PRIVATE

Status

11-50

Employees

Series C

Latest Deal Type

$7M

Latest Deal Amount

$50.5M

Total Amount Raised

Description

Developer of anti-bacterial drugs for the treatment of urinary tract infections. The company engages in research and development of anti-bacterial drugs for the treatment of urinary tract infections and the eradication of helicobacter pylori.

Website:

www.merlionpharma.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Pharmaceuticals

Primary Office

10 Raeburn Park Number 02-08 Singapore, 088702Singapore +65 6778 5700
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore MerLion Pharmaceuticals's full profile, request a free trial.

MerLion Pharmaceuticals Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

MerLion Pharmaceuticals Investors (17)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
AravisVenture CapitalMinority000 0000000 0000
Aurelia Private EquityVenture CapitalMinority000 0000000 0000
BC Brandenburg CapitalVenture CapitalMinority000 0000000 0000
Bio*One CapitalCorporate Venture CapitalMinority000 0000000 0000
BioVeda CapitalVenture CapitalMinority000 0000000 0000
Aravis Venture Capital
Aurelia Private Equity Venture Capital
BC Brandenburg Capital Venture Capital
Bio*One Capital Corporate Venture Capital
BioVeda Capital Venture Capital

MerLion Pharmaceuticals Executive Team (2)

NameTitleBoard
Seat
Contact
Info
David DallyChief Executive Officer
Andreas VenteManaging Director
David Dally Chief Executive Officer
Andreas Vente Managing Director

MerLion Pharmaceuticals Board Members (4)

NameRepresentingRoleSinceContact
Info
Clemens Doppler Ph.DHeidelbergCapitalCo-Founder & Managing Partner000 0000
Jean-Philippe TripetAravisFounder & Managing Partner000 0000
Simon Nebel Ph.DAravisManaging Partner000 0000
Swee Yeok ChuEDB InvestmentsChief Executive Officer, Board Member & President000 0000
Clemens Doppler Ph.D Co-Founder & Managing Partner HeidelbergCapital
Jean-Philippe Tripet Founder & Managing Partner Aravis
Simon Nebel Ph.D Managing Partner Aravis
Swee Yeok Chu Chief Executive Officer, Board Member & President EDB Investments
Request full access to PitchBook